CClinicalTrials.gg
RecruitingNCT07776301Updated Aug 20, 2026

Application of CT-Linac-Based "All-in-One" One-Stop Radiotherapy in Breast Cancer

An interventional study of Radiotherapy procedure in Breast Cancer, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Fudan University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
225
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate and report the clinical adverse events and dosimetric parameters in breast cancer patients undergoing an "all-in-one (AIO)" one-stop, fully automated radiotherapy workflow. By systematically tracking these clinical and physical metrics, we seek to establish a standardized clinical protocol for AIO radiotherapy in breast cancer management.

02

Conditions studied

  • Breast Cancer

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Histologically or pathologically confirmed breast cancer with definitive indications for radiotherapy (preoperative, postoperative, or radical)
  • ECOG performance status of 0-2
  • Able to remain still and supine on the treatment couch for up to 30 minutes
  • Provision of signed, written informed consent
  • Able to comply with daily follow-ups and blood sample collections

Exclusion criteria

Exclusion Criteria:

  • Palliative radiotherapy for concurrent distant metastasis
  • Incomplete or ongoing chemotherapy
  • Synchronous multiple primary tumors
  • Current pregnancy or lactation
  • Prior history of radiotherapy to the ipsilateral breast, chest wall, thorax, or regional lymph nodes
  • Severe non-malignant comorbidities (e.g., cardiovascular or pulmonary diseases, systemic lupus erythematosus, scleroderma) resulting in a short life expectancy or inability to tolerate radical radiotherapy
  • Inability or unlikelihood to comply with study follow-up
  • Inability or unwillingness to provide written informed consent
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
225 participants (estimated)

Study arms

  • Other
    ARM1: AI-empowered AIO WBI

    Evaluates the feasibility, safety, and patient experiences of the AI-empowered AIO workflow in breast cancer patients undergoing whole-breast irradiation (WBI) without regional nodal involvement.

    Other: Radiotherapy procedure

  • Other
    ARM2: Expanded-Scenario AIO RT

    Evaluates the feasibility, safety, and patient experiences of the AI-empowered AIO workflow in breast cancer patients with broader radiotherapy indications, including breast/chest wall irradiation with or without regional nodal radiotherapy.

    Other: Radiotherapy procedure

Interventions

  • OtherRadiotherapy procedure

    The workflow relies on specialized convolutional neural networks for automated segmentation and dose-prediction auto-planning. These breast cancer models were trained on 285 historical institutional cases spanning radical mastectomy and breast-conserving surgery over five years. Auto-delineated structures include the clinical target volume, regional lymph nodes (if involved), tumor bed (identified by surgical clips), heart, bilateral lungs, unaffected breast, spinal cord, esophagus, thyroid, and affected humeral head. These contours guide dose prediction to generate deliverable tangential arc plans via clinical-goal-guided automated optimization in the treatment planning system. To adapt to the on-couch treatment scenario, models were validated on retrospective data and offline routines to maximize target delineation accuracy and the first-approval rate of auto-plans.

05

What researchers measure

Primary outcomes

  1. Acute adverse events

    The incidence and severity of acute adverse event include radiation dermatitis, pruritus, skin pain, radiation esophagitis, and radiation pneumonitis.

    Time frame: 6 months

Secondary outcomes

  1. Accuracy

    Auto-segmentation accuracy was assessed by comparing automatically generated contours against the final physician-approved contours

    Time frame: 2 months

  2. Success rate

    Record AIO workflow success rate: online planning one-pass optimization success rate.

    Time frame: 2 months

  3. Quality of life (QoL)

    Quality of life will be evaluated via standardized QoL scales.

    Time frame: 6 months

  4. Time efficiency

    The time efficiency of the workflow was automatically recorded by the system

    Time frame: 2 months

  5. Full-Workflow Patient Intrafraction Motion

    Evaluated based on geometric deviations between pretreatment image-guided radiotherapy (IGRT), posttreatment imaging, and the baseline simulation CT

    Time frame: 2 months

  6. Correlation of Patient Metrology with Setup Error and Dosimetric Performance

    Evaluation of how Body Mass Index (BMI) and weight fluctuations correlate with geometric setup errors and in vivo gamma pass rates

    Time frame: 2 months

  7. Correlation of Anatomical Scale with Setup Error and Dosimetric Performance

    Evaluation of how anatomical scale/breast size correlates with geometric setup errors and in vivo gamma pass rates

    Time frame: 2 months

06

Study locations

1 of 1 sites recruiting
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Icf

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07776301
Lead sponsor
Fudan University
Responsible party
Xiaoli Yu (Professor, Fudan University) — Principal investigator
First posted
Aug 20, 2026
Start date
Aug 27, 2021
Primary completion
Aug 27, 2028 (estimated)
Completion
Nov 27, 2028 (estimated)
Last update
Aug 20, 2026

Study contacts

Xiaoli Yu, MD, PhD
Contact
xiaoliyu@fudan.edu.cn
+86-021-64175590
Xiaofang Wang, MD, PhD
Contact
xiaofang0708@yeah.net
+86 18017317247

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion